Analysts’ Recent Ratings Changes for Gilead Sciences (GILD)

02 Dec 2025, 11:02 by Doug Wharley · The Cerbat Gem

Several analysts have recently updated their ratings and price targets for Gilead Sciences (NASDAQ: GILD):

11/25/2025 – Gilead Sciences was given a new $135.00 price target on by analysts at BMO Capital Markets.
11/24/2025 – Gilead Sciences is now covered by analysts at Truist Financial Corporation. They set a “buy” rating and a $140.00 price target on the stock.
11/21/2025 – Gilead Sciences had its price target raised by analysts at Mizuho from $131.00 to $140.00. They now have an “outperform” rating on the stock.
11/15/2025 – Gilead Sciences was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
11/13/2025 – Gilead Sciences had its price target raised by analysts at Needham & Company LLC from $133.00 to $140.00. They now have a “buy” rating on the stock.
11/13/2025 – Gilead Sciences had its price target raised by analysts at Daiwa Capital Markets from $128.00 to $129.00. They now have an “outperform” rating on the stock.
11/13/2025 – Gilead Sciences is now covered by analysts at Scotiabank. They set a “sector outperform” rating and a $140.00 price target on the stock.
11/12/2025 – Gilead Sciences was upgraded by analysts at Scotiabank to a “strong-buy” rating.
11/10/2025 – Gilead Sciences had its price target raised by analysts at Rothschild & Co Redburn from $143.00 to $153.00.
11/4/2025 – Gilead Sciences had its price target raised by analysts at Argus from $130.00 to $135.00. They now have a “buy” rating on the stock.
11/3/2025 – Gilead Sciences had its “outperform” rating reaffirmed by analysts at Sanford C. Bernstein.
11/3/2025 – Gilead Sciences had its “buy” rating reaffirmed by analysts at Truist Financial Corporation. They now have a $145.00 price target on the stock, up previously from $127.00.
10/31/2025 – Gilead Sciences had its price target raised by analysts at JPMorgan Chase & Co. from $145.00 to $150.00. They now have an “overweight” rating on the stock.
10/31/2025 – Gilead Sciences had its price target raised by analysts at Royal Bank Of Canada from $100.00 to $105.00. They now have a “sector perform” rating on the stock.
10/31/2025 – Gilead Sciences had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $135.00 price target on the stock.
10/31/2025 – Gilead Sciences had its price target raised by analysts at Wells Fargo & Company from $140.00 to $145.00. They now have an “overweight” rating on the stock.
10/31/2025 – Gilead Sciences had its price target raised by analysts at Morgan Stanley from $143.00 to $147.00. They now have an “overweight” rating on the stock.
10/31/2025 – Gilead Sciences had its price target raised by analysts at The Goldman Sachs Group, Inc. from $108.00 to $110.00. They now have a “neutral” rating on the stock.
10/31/2025 – Gilead Sciences had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $133.00 price target on the stock.
10/23/2025 – Gilead Sciences had its price target raised by analysts at TD Cowen from $115.00 to $125.00. They now have a “buy” rating on the stock.
10/23/2025 – Gilead Sciences had its price target raised by analysts at Wolfe Research from $135.00 to $140.00. They now have an “outperform” rating on the stock.
10/20/2025 – Gilead Sciences had its price target raised by analysts at BMO Capital Markets from $130.00 to $135.00. They now have an “outperform” rating on the stock.
10/17/2025 – Gilead Sciences had its price target raised by analysts at The Goldman Sachs Group, Inc. from $105.00 to $108.00. They now have a “neutral” rating on the stock.
10/9/2025 – Gilead Sciences had its price target raised by analysts at Cantor Fitzgerald from $129.00 to $135.00. They now have an “overweight” rating on the stock.
10/8/2025 – Gilead Sciences had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
10/8/2025 – Gilead Sciences had its price target raised by analysts at Royal Bank Of Canada from $98.00 to $100.00. They now have a “sector perform” rating on the stock.
10/8/2025 – Gilead Sciences had its price target raised by analysts at Citigroup Inc. from $125.00 to $135.00. They now have a “buy” rating on the stock.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.99%.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $126.54, for a total value of $1,265,400.00. Following the transaction, the chief executive officer directly owned 571,203 shares of the company’s stock, valued at $72,280,027.62. This represents a 1.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $125.23, for a total value of $313,075.00. Following the sale, the chief financial officer owned 154,555 shares of the company’s stock, valued at approximately $19,354,922.65. This represents a 1.59% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 135,757 shares of company stock worth $16,616,127 in the last 90 days. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Analysts’ Recent Ratings Changes for Gilead Sciences (GILD)

Gilead Sciences Dividend Announcement

Insider Buying and Selling

Featured Stories